Table 1.
Baseline demographics and clinical characteristics of patients with axSpA receiving ixekizumab
| Variables | Patients with axSpA receiving ixekizumab (N = 177) |
|---|---|
| Baseline characteristics | |
| Age at index (years), mean (SD) | 45.8 (10.8) |
| Age (years), n (%) | |
| 18 to 44 | 79 (44.6) |
| 45 to 64 | 95 (53.7) |
| ≥ 65 | 3 (1.7) |
| Female, n (%) | 97 (54.8) |
| US region, n (%) | |
| South | 66 (37.3) |
| Midwest | 48 (27.1) |
| Northeast | 23 (13.0) |
| West | 15 (8.5) |
| Missing | 25 (14.1) |
| Payor at index date, n (%) | |
| Commercial | 174 (98.3) |
| Medicare | 2 (1.1) |
| Medicare advantage | 1 (0.6) |
| Clinical characteristics | |
| CCI score during pre-index period, mean (SD) | 1.1 (1.3) |
| CCI score categories, n (%) | |
| 0 | 77 (43.5) |
| 1 | 52 (29.4) |
| 2 | 23 (13.0) |
| 3 + | 25 (14.1) |
| Comorbidities, n (%) | |
| Malignancies | 21 (11.9) |
| Osteoarthritis | 55 (31.1) |
| Hyperlipidemia | 51 (28.8) |
| Obesity | 43 (24.3) |
| Cardiovascular diseasesa | 19 (10.7) |
| Osteoporosis | 13 (7.3) |
| Chronic gastritis | 9 (5.1) |
| Prior biologic useb, n (%) | 140 (79.1) |
| TNFic | 99 (70.7) |
| IL-17i (secukinumab) | 69 (49.3) |
| Prior biologic countd, mean (SD) | 1.0 (0.7) |
| Prior medication, n (%) | |
| NSAIDs | 106 (59. 9) |
| Oral corticosteroids | 93 (52.5) |
| csDMARDse | 39 (22.0) |
| Opioids | 39 (22.0) |
axSpA axial spondyloarthritis, CCI Charlson Comorbidity Index, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, IL-17i interleukin-17 inhibitor, NSAIDs nonsteroidal anti-inflammatory drugs, SD standard deviation, TNFi tumor necrosis factor-alpha inhibitors, US United States
aIncludes ischemic heart disease, heart failure, stroke, angina pectoris, cerebrovascular disease, coronary artery disease, and myocardial infarction
bUse of biologics adalimumab, secukinumab, infliximab, golimumab, etanercept, or certolizumab during pre-index period
cTNFi included adalimumab, infliximab, golimumab, etanercept, and certolizumab
dNumber of unique prior biologics refilled in the pre-index period
ecsDMARDs included methotrexate and sulfasalazine